In the South Court Auditorium in the White House complex on Friday, President Trump holds up an executive order he signed aimed at lowering drug prices. Alex Brandon/Associated Press
WASHINGTON — President Trump signed four executive orders aimed at lowering drug prices on Friday in an effort to shore up support among seniors ahead of the November election where he has been losing support in part because of his handling of the coronavirus crisis.
But his remarks are also likely to antagonize an industry he is relying on to develop treatments and vaccines to help end the coronavirus pandemic.
Trump has regularly complained to advisers that drug prices are too high, and some of his political advisers see health care as a key vulnerability in 2020. Several polls have shown that voters trust Democrats more on health care. The executive orders are variations of drug pricing proposals the administration rolled out last year.
However, the moves are largely symbolic because the orders are unlikely to take effect anytime soon, if they do so at all, since the power to implement drug pricing policy through executive order is limited. Voters will not see an impact before the November elections, and the drug industry is sure to challenge them in court.
“I’m not willing to wait any longer,” Trump said of lowering drug prices. “We’ve doing things that nobody thought could be done.”
Trump said he plans to meet with drug company executives on Tuesday to discuss their ideas for lowering prices, after they requested the meeting. White House aides spent much of Thursday fielding calls from executives expressing frustration the administration is pushing the orders even as it pushes the industry – including awarding companies billions of dollars – to develop and manufacture vaccines and treatments for COVID-19, the disease caused by coronavirus, according to a senior administration official and a Republican lobbyist.
Trump praised the administration’s work in pushing for the development of coronavirus treatments and a vaccine on a historically ambitious timeline, but did not laud the companies doing most of the research and development.
One of the orders would speed up the timeline for a proposal the administration introduced late last year to allow states, drug wholesalers and pharmacies to import certain drugs from Canada. Drug companies have pushed back fiercely on that proposal, arguing there is “no way to guarantee the safety of drugs that come into the country from outside the United States’ gold-standard supply chain.” The Canadian government also opposes the measure, warning that the drug supply for Canada’s 37 million residents cannot possibly fulfill the demands of the much larger U.S. market and that allowing importation would cause severe drug shortages for Canadians.
The political nature of Friday’s event was evidenced by the fact that Florida Gov. Ron DeSantis and Rep. Matt Gaetz, R-Fla., Trump allies, were in the audience. DeSantis lobbied the White House last year to allow states to import some drugs from Canada, where prices are far lower. Trump subsequently pushed his top health officials to draft an importation proposal in an effort to win over voters in a key swing state.
Another would tie some Medicare drugs’ prices to those paid in other countries with significantly lower list prices – a so-called “international pricing index” or “most favored nations” clause. The idea, which Trump called the “granddaddy of them all,” is anathema to most congressional Republicans, who see it as price fixing, as well as to the pharmaceutical industry.
The third proposal would end a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare, with the goal of channeling that money to consumers instead. Trump killed the rule last year, which is favored by the drug industry, after initially embracing it after seeing projections showing it would actually raise Medicare premiums.
The fourth proposal will require the provision of insulin and/or an EpiPen free through a program requiring pharmaceutical companies to provide steep discounts to thousands of hospitals and community health centers that serve large numbers of low-income patients. Drugmakers have targeted the program, known as 340B, arguing some facilities getting the discounts should not be eligible.
The executive orders were panned as an empty political gesture by at least one advocacy group pushing lower drug prices.
“These Executive Orders are not about policy, they’re about politics,” said Margarida Jorge, campaign director for Lower Drug Prices Now. “The only reason for President Trump’s rekindled interest in lowering drug prices is his dwindling poll numbers, and realization that our country’s senior citizens are abandoning him thanks to his bungled handling of the coronavirus crisis.”
White House Chief of Staff Mark Meadows has led the effort to turn previous administration proposals into executive orders the president could sign this summer, according to a senior administration official and two industry lobbyists who spoke on the condition of anonymity to discuss the plans. Several White House aides oppose the effort, arguing the administration should not alienate drug companies when it is so dependent on them for help ending the pandemic.
The administration has given the industry billions of dollars to aid with the development and manufacturing of vaccines, which some hold out as the only way to end a pandemic that has infected more than 4 million people and killed upward of 141,000. That includes a $1.95 billion contract awarded Wednesday to pharmaceutical giant Pfizer and German biotechnology firm BioNTech to supply the federal government with 100 million doses of their coronavirus vaccine – the administration’s largest investment yet in a vaccine that is still in development.
Trump has repeatedly pushed Health and Human Services Secretary Alex Azar and other aides to come up with drug pricing “wins” that he can tout on the campaign trail, but most of the administration’s proposals have not come to fruition. Infighting, a court ruling in favor of the drug industry and policy disputes have thwarted several of the administration’s previous efforts. Congress has also so far failed to pass White House-backed drug pricing legislation.
Copy the Story LinkComments are not available on this story.
Send questions/comments to the editors.
